BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32317009)

  • 1. Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.
    Raman L; Van der Linden M; Van der Eecken K; Vermaelen K; Demedts I; Surmont V; Himpe U; Dedeurwaerdere F; Ferdinande L; Lievens Y; Claes K; Menten B; Van Dorpe J
    Genome Med; 2020 Apr; 12(1):35. PubMed ID: 32317009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
    Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma.
    Staaf J; Isaksson S; Karlsson A; Jönsson M; Johansson L; Jönsson P; Botling J; Micke P; Baldetorp B; Planck M
    Int J Cancer; 2013 May; 132(9):2020-31. PubMed ID: 23023297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach.
    Beagan JJ; Drees EEE; Stathi P; Eijk PP; Meulenbroeks L; Kessler F; Middeldorp JM; Pegtel DM; Zijlstra JM; Sie D; Heideman DAM; Thunnissen E; Smit L; de Jong D; Mouliere F; Ylstra B; Roemer MGM; van Dijk E
    J Mol Diagn; 2021 Nov; 23(11):1553-1563. PubMed ID: 34454114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
    Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
    J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC.
    Mohan S; Foy V; Ayub M; Leong HS; Schofield P; Sahoo S; Descamps T; Kilerci B; Smith NK; Carter M; Priest L; Zhou C; Carr TH; Miller C; Faivre-Finn C; Blackhall F; Rothwell DG; Dive C; Brady G
    J Thorac Oncol; 2020 Feb; 15(2):216-230. PubMed ID: 31629061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
    Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
    J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
    Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
    Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients.
    Martignano F; Munagala U; Crucitta S; Mingrino A; Semeraro R; Del Re M; Petrini I; Magi A; Conticello SG
    Mol Cancer; 2021 Feb; 20(1):32. PubMed ID: 33579306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
    Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
    [No Abstract]   [Full Text] [Related]  

  • 14. Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer.
    Jang H; Choi CM; Lee SH; Lee S; Jeong MK
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level.
    Lu S; Chang CJ; Guan Y; Szafer-Glusman E; Punnoose E; Do A; Suttmann B; Gagnon R; Rodriguez A; Landers M; Spoerke J; Lackner MR; Xiao W; Wang Y
    J Mol Diagn; 2020 Jun; 22(6):770-781. PubMed ID: 32247862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
    Guibert N; Pradines A; Favre G; Mazieres J
    Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
    Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
    Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer.
    Karlsson A; Cirenajwis H; Ericson-Lindquist K; Brunnström H; Reuterswärd C; Jönsson M; Ortiz-Villalón C; Hussein A; Bergman B; Vikström A; Monsef N; Branden E; Koyi H; de Petris L; Micke P; Patthey A; Behndig AF; Johansson M; Planck M; Staaf J
    Sci Rep; 2019 Mar; 9(1):5207. PubMed ID: 30914778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large fragment Bst DNA polymerase for whole genome amplification of DNA from formalin-fixed paraffin-embedded tissues.
    Aviel-Ronen S; Qi Zhu C; Coe BP; Liu N; Watson SK; Lam WL; Tsao MS
    BMC Genomics; 2006 Dec; 7():312. PubMed ID: 17156491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
    Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
    Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.